TOPIC
Neuroleptic Malignant Syndrome (NMS) is a rare but specifi c lethal reaction to neuroleptics / antipsychotics. Neuroleptic malignant syndrome related to the treatment of antipsychotic haloperidol was fi rst described in 1960 by the Delay and associates [1] . Although estimates incidence of neuroleptic malignant syndrome used to be even 3% of patients treated with antipsychotics, more recent data suggests incidence of 0.01% -0.02% [2] . It is most oft en associated with typical highly potent antipsychotic drugs (e.g. haloperidol, fl uphenazine) [3] . However, every class of antipsychotics implied, including low potent (e.g. chlorpromazine), newer atypical antipsychotics (e.g. clozapine, risperidone, olanzapine) and antiemetic medicines (e.g. metoclopramide, promethazine). Neuroleptic malignant syndrome is characterized by fever, muscle rigidity, altered mental status, autonomic dysfunction and increased creatine kinase [4 -5] .
TOPIC POSITION IN MEDICAL PUBLIC
Pathophysiology Although the precise pathophysiological mechanisms related to neuroleptic malignant syndrome have not been proven, the blockade of dopamine due to antipsychotics, plays a ma-jor role as a trigger for this condition [6] . Several arguments support this assumption:
• withdrawal of dopaminergic drugs participating in neuroleptic malignant syndrome; • all drugs associated with malignant neuroleptic syndrome caused by dopamine receptor blockade;
• seems that the risk of neuroleptic malignant syndrome correlates with affi nity of drugs for binding to dopamine receptors; • dopaminergic drugs are used to treat neuroleptic malignant syndrome, and it is noticed that patients with lesions of the central dopamine pathways develop syndromes sharing many clinical characteristics with neuroleptic malignant syndrome.
Th e central role of dopaminergic hypofunction is further supported by observation that the concentration of dopamine metabolites and homovanillic acid in cerebrospinal fl uid is low in patients with acute neuroleptic malignant syndrome [7] . Polymorphisms in the dopamine 2 receptor gene in patients who have recovered from neuroleptic malignant syndrome have been researched in several preliminary studies, although the results are not consistent [8] . However, the direct eff ect on peripheral skeletal muscles may have an additional role. Based on autonomic dysfunction observed in the last two decades related to the neuroleptic malignant syndrome and on observed increased values of catecholamine in many cases, it was pointed out that symphatoadrenal dysfunction has a role in contributing to neuroleptic malignant syndrome. Whatever mechanism causes neuroleptic malignant syndrome, pathophysiology of neuroleptic malignant syndrome is probably complicated and includes dysregulation cascade of multiple neurochemical and neuroendocrine system that culminate on the closing stage of hypermetabolic syndrome [9] .
Pathogenesis
Neuroleptic malignant syndrome may occur as a result of changes in pre-/or posthypnotic dopaminergic signals. Th ere are two mechanisms: 1. Reduced DA signals as a result of the sudden withdrawal of dopaminergic drugs. 2. Initiating the agents which block DA signals [9] .
Th ere is great probability that neuroleptic malignant syndrome shall occur aft er starting treatment with antipsychotics or aft er increasing doses of the drug. Initiating neuroleptic malignant syndrome symptom may occur aft er a few hours, but on average, begins from 4 to 14 days aft er starting treatment.
Four characteristics that defi ne neuroleptic malignant syndrome are as follows: 1. Motor symptoms 2. Altered mental status 3. Hyperthermia 4. Autonomic instability.
Motor symptoms
Due to inclusion of the basal ganglia, the primary motor characteristic is rigidity or socalled 'lead bar' . Other motor irregularities include akinesia/bradykinesia, dystonia, inability to speak, chorea, dysarthria and tremor [10] .
Altered mental status
Alternations in mental status ranging from confusion, delirium and stupor to coma are very common at neuroleptic malignant syndrome [11] .
Hyperthermia Fever higher than 38 ° C oft en occurs, and sometimes exceeds 41 ° C [12] .
Autonomic instability
Autonomic dysfunction is manifested by respiratory irregularities, cardiac arrhythmia, variable blood pressure, incontinence and diaphoresis [13] .
Diagnosis
Despite the available criteria, it is usually hard to distinguish neuroleptic malignant syndrome from frequent extrapyramidal undesired effects and other disorders occurring in similar symptoms; Criteria for researching DSM IV TR require presence of strong muscular rigidity and increased fever aft er the imminent application of antipsychotics. All three main criteria (fever, rigidity, increased serum creatine kinase), or two main and four secondary criteria (tachycardia, variable blood pressure, altered state of consciousness, diaphoresis, leukocytosis) indicate great probability of neuroleptic malignant syndrome if corroboratedclinically [14] . Laboratory tests include:
• Increased serum creatine kinase (CK); • Other laboratory irregularities [3] .
Increased serum creatine kinase: In neuroleptic malignant syndrome, CK is usually higher than 1.000 IU/L and may reach 100.000 IU/L. Increased CK value shows rhabdomyolysis as secondary in respect of muscular rigidity. It seems that the level of increased CK is in direct correlation with seriousness of the disease and higher value in accordance with prognosis [2 3] . Th e second most consistent fi nding is leukocytosiswith white blood cell count of 10. 000 to 40. 000. Laboratory value of leukocytes can be shift ed to left . Lactate dehydrogenase (LDH), alkaline phosphatase, and liver transaminase are frequently leniently increased. Irregularities of electrolytes in terms of hypocalcemia, hypo-or hypernatremia, hyperkalemia and metabolic acidosis are oft en noticed. Myoglobinuric acute renal failure may be the result of rhabdomyolysis. Low concentration value of iron in serum (mid value 5.71μmol/L) is oft en found in neuroleptic malignant syndrome and it is sensitive but not specifi c marker for neuroleptic malignant syndrome in acute patients.
Serious cases of neuroleptic malignant syndrome may be followed by stupor and coma. In these circumstances, lumbar puncture CSF may be implied to evaluate alternative cause and determine whether there is a threatening cerebral edema due to metabolic disorders.
Diff erential diagnosis of neuroleptic malignant syndrome divide into two categories: Intensive monitoring and supportive treatment require admission to the intensive care unit. Th e following supportive treatment should be provided:
• canceling antipsychotic drug administration or precipitating medicine • maintaining cardiorespiratory stability. However, mechanic ventilation and antiarrhythmicdrugs may be required.
• maintaining euvolemic state using intravenous fl uids. Unplanned loss of fl uids due to fever and diaphoresis should be also considered.
• decreasing temperature by chilling and using antipyretics.
•decreasing blood pressure, if it is signifi cantly increased 
KRATAK SADRŽAJ
Tema: Maligni neuroleptički sindrom je retka, ali po život opasna osobena reakcija na neuroleptike/ antipsihotike. Javlja se kod 0,02% do 3,3% pacijenata koji u terapiji koriste konvencionalne neuroleptičke lekove. Maligni neuroleptički sindrom povezuje se sa visokopotentnim antipsihotičkim lekovima. Međutim, može da se javi i kod bolesnika lečenim atipičnim antipsihoticima, češće kod primene klozapina. Pozicioniranost teme u medicinskoj javnosti: Maligni neuroleptički sindrom je hitno stanje u medicini, komplikacija potencijalno opasna po život povezana sa neželjenim dejstvom neuroleptičkih lekova. Visok nivo kreatin kinaze (CK) i leukocitoza povezani su sa maignim neuroleptičkim sindromom. Buduće aktivnosti: Maligni neuroleptički sindrom kao psihijatrijski entitet zahteva permanentna istraživanja, ranu dijagnozu, adekvatnu terapiju, razmenu kliničkih iskustava, i što je od posebnog značaja, racionalnu upotrebu antipsihotika.
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